Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BECN1 | Q14457 | 11/20 | 0.63 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.60 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.58 |
| ▸ | NPR1 | P16066 | 1/20 | 0.57 |
| ▸ | NPR3 | P17342 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | RXFP4 | Q8TDU9 | 3/20 | 0.56 |
| ▸ | RXFP3 | Q9NSD7 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236232 | 0.95 | BECN1 (0.70) | BECN1KCNMA1KCNMB4INSRALB | |
| SCHEMBL14654850 | 0.92 | BECN1 (0.67) | BECN1KCNMA1KCNMB4INSRALB | |
| SCHEMBL17236230 | 0.91 | BECN1 (0.66) | BECN1KCNMA1KCNMB4INSRALB | |
| SCHEMBL8991433 | 0.91 | BECN1 (0.63) | BECN1KCNMA1KCNMB4INSRALB | |
| SCHEMBL8991534 | 0.91 | BECN1 (0.59) | BECN1KCNMA1KCNMB4INSRALB | |
| SCHEMBL29607029 | 0.80 | CSNK2A2 (0.67) | BECN1KCNMA1KCNMB4INSRCSNK2A2 | |
| Iseganan SCHEMBL29378977 | 0.79 | CTSG (0.56) | BECN1KCNMA1KCNMB4ALBCSNK2A2 | |
| Protegrin 1 SCHEMBL29352276 | 0.78 | F12 (0.54) | BECN1KCNMA1KCNMB4 | |
| Iseganan SCHEMBL29420585 | 0.78 | CTSG (0.55) | BECN1KCNMA1KCNMB4ALBCSNK2A2 | |
| SCHEMBL14840198 | 0.78 | INSR (0.93) | KCNMA1KCNMB4INSRCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| CN-118209669-A | Solid phase extraction-liquid chromatography-mass spectrometry detection method for small peptide substances in dry blood spots | 北京体育大学 | 2024-06-18 | — | — | CN | claimed |
| CN-116973466-A | Solid phase extraction-liquid chromatography-mass spectrometry detection method for small peptide substances | 北京体育大学 | 2023-10-31 | — | — | CN | claimed |
| CN-107614695-B | Methods of treating obesity and non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with glucagon receptor antagonist antibodies | 瑞美德生物医药科技有限公司 | 2022-01-25 | — | — | CN | claimed |
| EP-4743083-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | Pleiogenix Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| CN-121851142-A | Synthesis method of AOD-9604 polypeptide | 杭州贝普泰生物医药有限公司 | 2026-04-14 | — | — | CN | disclosed |
| CN-121851142-A | Synthesis method of AOD-9604 polypeptide | 杭州贝普泰生物医药有限公司 | 2026-04-14 | — | — | CN | disclosed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO, LLC | 2022-03-03 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | SOLENO THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| CN-111630058-B | Glucopyranosyl derivative and use thereof | 广东东阳光药业有限公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20220023299-A1 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | PFIZER INC. (US) | 2022-01-27 | — | — | US | disclosed |
| CN-107614695-B | Methods of treating obesity and non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with glucagon receptor antagonist antibodies | 瑞美德生物医药科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | BECN1 3953/4885KCNMA1 3646/4885KCNMB4 3775/4885 |
| US-20220047605-A1 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF | KCNJ1, KCNJ11, KCNJ2 | BECN1 1983/4885KCNMA1 44/4885KCNMB4 63/4885 |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | BECN1 2061/4885KCNMA1 4425/4885KCNMB4 4548/4885 |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | FABP1, PPARG, GOT2 | BECN1 205/4885KCNMA1 4601/4885KCNMB4 4342/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | BECN1 1454/4885KCNMA1 2040/4885KCNMB4 2659/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | BECN1 3634/4885KCNMA1 3844/4885KCNMB4 2069/4885 |
| US-20220023299-A1 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | FABP1, PPARG, GOT2 | BECN1 205/4885KCNMA1 4601/4885KCNMB4 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.